Pulmonary tuberculosis curative effect evaluation kit and its application

A curative effect evaluation and kit technology, which is applied in the field of pulmonary tuberculosis curative effect evaluation kits, can solve the problems of time-consuming, easy misdiagnosis, and poor discrimination efficacy, and achieve the effects of high efficiency, easy operation, high sensitivity and specificity

Active Publication Date: 2016-05-18
李继承
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, clinical judgment methods such as the patient's mental state and chest X-ray / CT imaging changes are too subjective, and it is easy to misdiagnose; the sputum culture examination takes too long, taking 4-8 weeks, and the resolution is poor, with a specificity of only 57.8 %

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pulmonary tuberculosis curative effect evaluation kit and its application
  • Pulmonary tuberculosis curative effect evaluation kit and its application
  • Pulmonary tuberculosis curative effect evaluation kit and its application

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0040] Embodiment 1: the composition of pulmonary tuberculosis curative effect evaluation kit

[0041] In this embodiment, the tuberculosis curative effect evaluation kit includes microtiter plate, protein standard composition, biotin-labeled antibody composition, horseradish peroxidase-labeled avidin, diluent, washing solution, bottom reagent solution, stop solution, microtiter plate stickers.

[0042] The microtiter plates include: anti-ALB antibody-coated microtiter plates, anti-APOA antibody-coated microtiter plates, anti-C3 antibody-coated microtiter plates, and the above microtiter plates were purchased from Abcam Aimei Jie Technology Co., Ltd. . Also included are anti-ARHGDIB antibody-coated microtiter plates and anti-FCN2 antibody-coated microtiter plates, which were purchased from Wuhan Huamei Bioengineering Co., Ltd.

[0043]In this embodiment, the protein standard composition includes: ALB, APOA, ARHGDIB, C3 and FCN2 five protein standards. Among them, the ALB, A...

Embodiment 2

[0060] Example 2: Establishment of the Logistic stepwise regression model of the pulmonary tuberculosis curative effect evaluation kit

[0061] Tuberculosis efficacy evaluation kit was used to detect the expression levels of ALB, APOA, ARHGDIB, C3 and FCN2 proteins in the serum of untreated tuberculosis patients, cured tuberculosis patients, and healthy controls.

[0062] (1) Sample collection:

[0063] According to the diagnostic criteria of tuberculosis issued by the Ministry of Health of China, 57 cases of tuberculosis patients who did not take drugs were collected, and 59 cases of tuberculosis patients were cured. During the same period, 60 cases of healthy controls were collected. All HIV tests were negative, no hepatitis B, no diabetes, no asthma, no history of tuberculosis, normal liver and kidney function, no other congenital diseases, and other diseases such as chronic inflammation and autoimmune diseases were excluded. There was no other operation history, and there...

Embodiment 3

[0084] Example 3: Verification and application of the detection effect of the pulmonary tuberculosis curative effect evaluation kit

[0085] Leave-one-out cross-validation: take serum samples from cured tuberculosis patients, drug-naïve tuberculosis patients, and normal controls, and the sample collection and dilution methods are the same as those described in Example 2.

[0086] Add 0.1 mL of the diluted serum to be tested to the microtiter plate coated with anti-ALB antibody, anti-APOA antibody, anti-ARHGDIB antibody, anti-C3 antibody and anti-FCN2 antibody, and incubate at 37°C for 1 hour.

[0087] Pat the microtiter plate dry, add 0.1 mL of freshly diluted biotin-labeled antibody to each reaction well corresponding to the antibody coated on the microtiter plate, incubate at 37°C for 1 hour, and wash with washing solution.

[0088] Add 0.1 mL of freshly diluted horseradish peroxidase-labeled avidin to each reaction well, incubate at 37°C for 0.5-1 hour, and wash with washin...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Sensitivityaaaaaaaaaa
Login to view more

Abstract

The invention discloses a curative effect evaluation reagent kit of phthisis, which comprises five elisa plates, a protein standard composition and a biotin labeled antibody composition, wherein the elisa plates are coated with an ALB (Albumin) antibody, an APOA (Lipoprotein A) antibody, a C3 antibody, an ARHGDIB (Rho GDP Dissociation Inhibitor) antibody and an FCN2 (Ficolin-2) antibody respectively; the protein standard composition comprises an ALB protein standard, an APOA protein standard, an ARHGDIB protein standard, a C3 protein standard and an FCN2 protein standard; and the biotin labeled antibody composition comprises a biotin-labeled ALB antibody, a biotin-labeled APOA antibody, a biotin-labeled ARHGDIB antibody, a biotin-labeled C3 antibody and a biotin-labeled FCN2 antibody. The curative effect evaluation reagent kit of the phthisis can evaluate a curative effect of a phthisis patient efficiently and accurately.

Description

technical field [0001] The invention relates to the field of disease curative effect evaluation, in particular to a tuberculosis curative effect evaluation kit and its application. Background technique [0002] Pulmonary tuberculosis is a chronic pulmonary infectious disease caused by Mycobacterium tuberculosis infection, and its infection rate and mortality rate are high. At present, there is no clear evaluation index for the efficacy of tuberculosis in my country, which is easy to over-treat, resulting in increased toxic and side effects of patients, increased economic burden, and waste of medical resources. Therefore, there is an urgent need to study specific biomarkers for evaluating the efficacy of tuberculosis, so as to alleviate the burden of tuberculosis on individuals, families, and society. [0003] At present, the evaluation of the efficacy of tuberculosis is mainly based on the experience of clinicians and the results of sputum culture experiments to identify wh...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): G01N33/68
CPCG01N33/6893G01N2800/12G01N2800/52G01N2800/70
Inventor 李继承王冲
Owner 李继承
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap